Evidence map›Paper›PMID 35269838›Full record

ArticleInternational journal of molecular sciences2022

Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer.

Sabine Heublein, Udo Jeschke, Cornelia Sattler, Christina Kuhn, Anna Hester, Bastian Czogalla, Fabian Trillsch, Sven Mahner, Doris Mayr, Elisa Schmoeckel and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sabine HeubleinDepartment of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany.
Udo JeschkeDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-2623-3235
Cornelia SattlerDepartment of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany.
Christina KuhnDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.
Anna HesterDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.
Bastian CzogallaDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.ORCID 0000-0001-6589-4736
Fabian TrillschDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-1860-4350
Sven MahnerDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.
Doris MayrDepartment of Pathology, LMU Munich, 80337 Munich, Germany.
Elisa SchmoeckelDepartment of Pathology, LMU Munich, 80337 Munich, Germany.
Nina DitschDepartment of Obstetrics and Gynecology, University Hospital LMU Munich, 81377 Munich, Germany.
LMU Klinikum · DEUniversity of Augsburg · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since the most well-known function of thyroid hormone receptors (TRs) relies on their ability to act as ligand-activated transcription factors, their subcellular localization has been recognized to be relevant for their biological meaning. The current study aimed to determine the prevalence and subcellular distribution of TR beta and TR beta-1 in ovarian cancer (OC). Methods: Tissue was collected from 153 patients that had undergone surgery due to OC at the Department of Obstetrics and Gynaecology of the Ludwig-Maximilians-University Munich. Immunohistochemistry detecting TR beta and TR beta-1 was performed. Staining signals were quantified and tested for association with clinico-pathological parameters including overall survival (OS). Results: The subcellular distribution of TR beta and TR beta-1 differed among histologic subtypes, grade and FIGO stage. TR beta positivity was strongly linked to shortened overall survival (p < 0.001). Strikingly, this shortened OS was mainly attributed to those cases showing complete (p = 0.005) or incomplete shift of TR beta to the cytoplasm (p < 0.001). Significance was lost in multivariate testing. Conclusions: Cytoplasmatic localization of TR beta was associated with reduced OS, at least in univariate analysis. Since TRs have long been supposed to mainly function via the regulation of gene transcription in the nucleus, cytoplasmatic shifting might be interpreted as a regulator of their activity.

Indexed as

Ovarian NeoplasmsThyroid Hormone Receptors betaCell NucleusHumansReceptors, Thyroid HormoneTranscription FactorsTriiodothyronineReceptors, Thyroid HormoneThyroid Hormone Receptors betaTranscription FactorsTriiodothyronineovarian cancerprognosisthyroid hormone receptor beta

Identifiers

PMID35269838
PMCPMC8910424
OpenAlexW4214563857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.